Five things for pharma marketers to know: Tuesday, September 27, 2016
1. Amgen's multiple myeloma treatment Kyprolis failed to best Takeda Pharmaceuticals' Velcade in a Phase-III trial. The trial failed to meet its primary endpoint in showing superiority in terms of progression-free survival for multiple myeloma patients.
2. Only one in 13 experimental diabetes drugs that entered clinical trials from 1995 to 2007 received FDA approval, a statistic that is lower than the one-in-eight approval rate for all investigational drugs, according to an analysis by the Tufts Center for the Study of Drug Development. The chances of approval for a diabetes drug in late-stage testing were higher than other drugs, though. Diabetes drugs in Phase-III trials had a 60% chance of approval, compared to 56% for all other drugs in late-stage studies. (Stat)
3. Some shareholders are reportedly upset with GlaxoSmithKline's decision to promote Emma Walmsley to CEO. Some investors wanted an “external appointment” and questioned whether Walmsley would follow a different strategy than Andrew Witty. (The Telegraph)
4. Bayer's dermatology business is reportedly drawing interesting from a range of drugmakers, including Lupin Pharmaceuticals and Mylan. The portfolio includes eczema treatment Desonate and rosacea medicine Finacea. (Bloomberg)
5. Kite Pharma released new data from its Phase-II trial of its CAR-T therapy, KTE-C19. The trial showed that 39% of the patients with non-Hodgkin's lymphoma who participated in the trial had a complete response, meaning their cancer disappeared. (Xconomy)